论文部分内容阅读
目的探讨奥扎格雷钠对非ST段抬高的心肌梗死(non-ST-segment elevation myocardial infarction,NSTEMI)患者血栓素B2(thromboxaneB2,TXB2);6-酮-前列腺素(6-K-PGF1a)的影响。方法对81例NSTEMI患者随机分为对照组和奥扎格雷钠注射液治疗组,观察治疗前后血浆TXB2、6-K-PGF1a水平。结果NSTEMI患者应用奥扎格雷钠治疗后,血浆TXB2明显下降(P<0.05),6-K-PGF1a明显升高(P<0.05))。结论应用奥扎格雷钠注射液治疗NSTEMI有一定价值。
Objective To investigate the effect of ozagrel on thromboxane B2 (TXB2), 6-keto-prostaglandin (6-K-PGF1a) in non-ST-segment elevation myocardial infarction Impact. Methods 81 patients with NSTEMI were randomly divided into control group and ozagrel sodium injection treatment group before and after treatment to observe the level of TXB2, 6-K-PGF1a. Results After treatment with ozagrel sodium in NSTEMI patients, plasma TXB2 was significantly decreased (P <0.05) and 6-K-PGF1a was significantly increased (P <0.05). Conclusion The application of ozagrel sodium injection in the treatment of NSTEMI has some value.